Could a drug cocktail boost brain function in early dementia?

NCT ID NCT06467539

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding an antioxidant to an NMDA-enhancing drug (DAOIB) improves thinking and memory more than the drug alone in people with early Alzheimer's or mild cognitive impairment. Eighty participants will take the combination or a placebo for 24 weeks. Researchers will measure changes in cognitive tests and daily function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DAOIB (an NMDA-enhancing agent) plus an antioxidant
What this could lead to: If successful, this could point toward a new combination treatment that slows cognitive decline in early Alzheimer's or mild cognitive impairment.
What could go wrong: This is a small Phase 2 trial with only 80 participants, so results may not be conclusive. The combination may not work better than DAOIB alone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE MILD COGNITIVE IMPAIRMENT

Contacts and locations

Locations

Chang Gung Memorial Hospital
RECRUITING

Kaohsiung City, 886, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.